| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | - | - | - | - | - | - | 1.727 | 3.524 | 6.812 | 3.887 |
| Total Income - EUR | - | - | - | - | - | - | 1.727 | 3.535 | 6.814 | 3.888 |
| Total Expenses - EUR | - | - | - | - | - | - | 313 | 454 | 509 | 555 |
| Gross Profit/Loss - EUR | - | - | - | - | - | - | 1.414 | 3.082 | 6.305 | 3.332 |
| Net Profit/Loss - EUR | - | - | - | - | - | - | 1.362 | 2.978 | 5.316 | 2.879 |
| Employees | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
Check the financial reports for the company - Udreamed Oncotrial S.r.l.
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Current Assets | - | - | - | - | - | - | 1.633 | 3.062 | 5.614 | 3.561 |
| Inventories | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Receivables | - | - | - | - | - | - | 0 | 1.893 | 4.027 | 392 |
| Cash | - | - | - | - | - | - | 1.633 | 1.169 | 1.587 | 3.168 |
| Shareholders Funds | - | - | - | - | - | - | 1.403 | 3.027 | 5.365 | 3.404 |
| Social Capital | - | - | - | - | - | - | 40 | 41 | 40 | 40 |
| Debts | - | - | - | - | - | - | 230 | 35 | 249 | 157 |
| Income in Advance | - | - | - | - | - | - | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Udreamed Oncotrial S.r.l.